Table 3 Predictive value (PPV), Sensitivity, AUC (area under the curve) and their 95% confidence intervals (CI) of all cancer patients and by cancer types, using the Swedish Cancer Register as ‘gold standard’ reference
Cancer Register | Skåne Healthcare Register | ||||
|---|---|---|---|---|---|
Number of cancer patientsa | Number of cancer patientsa | PPV (95%CI), % | Sensitivity (95%CI), % | AUC (95%CI) | |
All cancers | 61,693 | 87,650 | 63.76 (63.44–64.08) | 90.58 (90.35–90.81) | 0.94 (0.94–0.94) |
Cancers of lip, oral cavity and pharynx | 1142 | 1298 | 72.85 (70.21–75.38) | 74.96 (72.34–77.45) | 0.87 (0.86–0.89) |
Cancers of digestive organs | 10,549 | 11,877 | 80.13 (79.38–80.86) | 85.99 (85.31–86.65) | 0.93 (0.93–0.93) |
Esophagus | 523 | 465 | 89.03 (85.83–91.72) | 79.16 (75.42–82.56) | 0.90 (0.88–0.91) |
Colorectal | 6837 | 6774 | 88.22 (87.43–88.98) | 87.41 (86.60–88.18) | 0.94 (0.93–0.94) |
Liver | 902 | 1059 | 55.43 (52.38–58.45) | 65.08 (61.87–68.19) | 0.83 (0.81–0.84) |
Pancreas | 930 | 1432 | 53.49 (50.87–56.10) | 82.37 (79.76–84.76) | 0.91 (0.90–0.92) |
Cancers of lung and thorax | 5244 | 5381 | 84.64 (83.61–85.63) | 80.68 (79.59–81.74) | 0.90 (0.90–0.91) |
Bronchus and lung | 4916 | 4502 | 86.34 (85.30–87.33) | 79.07 (77.90–80.20) | 0.90 (0.89–0.90) |
Bone cancer | 95 | 240 | 43.40 (35.57–51.48) | 72.63 (62.52–81.28) | 0.86 (0.82–0.91) |
Skin cancer | 7434 | 29,371 | 20.08 (19.60–20.56) | 73.94 (72.93–74.94) | 0.86 (0.86–0.87) |
Melanoma skin cancer | 3104 | 3267 | 74.64 (73.07–76.16) | 74.81 (73.24–76.33) | 0.87 (0.87–0.88) |
Non-melanoma skin cancer | 4330 | 26,104 | 11.50 (11.09–11.91) | 63.28 (61.82–64.72) | 0.81 (0.80–0.82) |
Cancers of soft tissues | 361 | 797 | 52.74 (47.73–57.71) | 58.73 (53.45–63.85) | 0.79 (0.77–0.82) |
Breast cancer | 8681 | 9451 | 87.31 (86.62–87.98) | 93.74 (93.21–94.25) | 0.97 (0.97–0.97) |
Other female genital cancers | 3029 | 3476 | 81.70 (80.34–83.01) | 88.61 (87.42–89.72) | 0.94 (0.94–0.95) |
Uterus | 1293 | 1166 | 92.28 (90.60–93.75) | 83.22 (81.07–85.22) | 0.92 (0.91–0.93) |
Male genital cancers | 11,318 | 11,356 | 89.43 (88.84–90.00) | 88.06 (87.45–88.66) | 0.94 (0.94–0.94) |
Prostate | 10,748 | 10,421 | 90.53 (89.95–91.08) | 87.77 (87.14–88.39) | 0.94 (0.94–0.94) |
Cancers of urinary tract | 4526 | 4937 | 83.65 (82.57–84.70) | 87.41 (86.40–88.36) | 0.94 (0.93–0.94) |
Kidney | 1224 | 1402 | 74.04 (71.66–76.32) | 84.80 (82.67–86.77) | 0.92 (0.91–0.93) |
Bladder | 3302 | 3219 | 87.57 (86.38–88.69) | 85.37 (84.12–86.56) | 0.93 (0.92–0.93) |
Cancers of central nervous system and eye | 1712 | 1452 | 66.81 (64.24–69.31) | 53.15 (50.76–55.54) | 0.77 (0.75–0.78) |
Cancers of endocrine glands | 1647 | 671 | 73.19 (69.53–76.64) | 27.69 (25.54–29.92) | 0.64 (0.63–0.65) |
Hematologic malignancies | 4117 | 4779 | 75.45 (74.17–76.69) | 84.11 (82.96–85.22) | 0.92 (0.91–0.93) |
Others | 1838 | 2564 | 41.69 (39.04–44.38) | 30.58 (28.48–32.74) | 0.65 (0.64–0.66) |